Board of Directors
Thomas A. Albright
President and CEO, Board Director
Mr. Albright was formerly Chairman and CEO of Andrew Technologies LLC from 2011 to 2017. In the past, Mr. Albright was President of the topical aesthetic division at Syneron Medical Ltd. and before that Head of North American marketing at Nobel Biocare. From 2000 to 2008, Mr. Albright was VP BOTOX Global Strategic Marketing at Allergan, where he led the U.S. launch of BOTOX Cosmetic and the commercial development of Latisse. He started his medical industry experience in 1983 at Parke-Davis division of Warner Lambert, where he was a Director of Marketing on the Lipitor launch team. Mr. Albright was also a Board director of Bonti Inc. prior to its acquisition by Allergan. Mr. Albright has a BS in biology from The Citadel and an MBA in marketing from Mercer University.
Milind K. Ambe M.D.
Board Director, Chairman of the Scientific Advisory Board
Dr. Ambe is a board certified Plastic Surgeon with over 20 years of experience in Newport Beach, California. He is the founder and CEO of the Newport Center Surgical, a multispecialty surgery center of excellence. He is also the founder Ambe Aesthetics, a non-surgical aesthetic center of excellence. Dr. Ambe is also the Chairman of the Company’s Scientific Advisory Board. He graduated Magna Cum Laude from the University of California and received his medical degree with honors from the University of California Medical School in Irvine, California. He has authored several articles in Plastic Surgery including the “The Latest Advances in Aesthetic Plastic Surgery.”
David F. Hale
Chairman of the Board, Founder
Mr. Hale is Chairman of Hale BioPharma Ventures, LLC, a private investment fund. He is also; Chairman of Adigica Health, Biocept, Cassiopea, Clarify Medical, Colorescience, Conatus, Dermata, MDRejuvena, Neurelis and Neurana Pharmaceuticals. In the non-profit world, Mr. Hale is Chairman at Rady Children’s Institute for Genomic Health; Director of Rady Children’s Hospital, the Salk Institute, CONNECT and BIOCOM. He is the former Chairman of Crisi, Santarus, SkinMedica, Micromet, and Somaxon; and a former President and CEO of CancerVax, Gensia and Hybritech.
Charlie Huiner serves as President & CEO of Treble Life Sciences LLC, where he provides strategic and corporate development advisory services to early and commercial stage life science companies. Prior to founding Treble in 2019, he served in senior operating roles within the aesthetics and telehealth sectors, leading a number of transformative strategic transactions and successful financial exits. Most recently Mr. Huiner served as Chief Operating Officer and Senior Vice President, Corporate Development and Strategy for Sientra, Inc. From 2007 to 2014, he was Vice President of Business Development and Marketing at InTouch Health. Before that, Mr. Huiner served in senior corporate development and strategy roles at Isolagen and INAMED, Inc (now Allergan Aesthetics). Prior to that, he served in various corporate investing and operating positions, and as an M&A financial analyst at NatWest Bancorp. Mr. Huiner earned an MBA in finance and marketing from Northwestern University’s Kellogg School and a BA in history and American studies from Williams College.
Mark J. Kerslake
Mr. Kerslake is Principal of the Province Group, a Newport Beach, CA real estate development and investment company active in the acquisition, entitlement, management, and disposition of residential and mixed-use real estate projects in multiple states. Mr. Kerslake has considerable experience in transactional structuring, financial engineering and high-level negotiations with buyers, sellers, lenders and institutional financial partners. Mr. Kerslake holds a MBA from UCLA.
Edward Knowlton, M.D.
Founder, Board Director
Dr. Knowlton is a board certified Plastic Surgeon with over 30 years of experience and is a graduate of Washington University Medical School in St. Louis. As the founder of Thermage (a publicly traded company), he was the principle inventor and developer of the ThermaCool TC System that tightens skin non-invasively. Dr. Knowlton has authored over 100 medical device patents and has published several articles on Plastic Surgery including an innovative approach to Breast Reconstruction called “The Peg Procedures.”
Mitchell E. Levinson
Mitchell E. Levinson co-founded Cerebrotech Medical Systems, Inc., a neurotechnology device company focused on the development of portable neurotechnology solutions in 2010, and is currently the Chief Technology Officer. Prior to 2010, Mr. Levinson was the start-up CEO for Zeltiq Aesthetics, Inc. when he became its first employee in 2005, and served as its president and its Chief Executive Officer from September 2005 until September 2009. He continued with Zeltiq as Chief Scientific Officer from September 2009 through December 2010. From March 2000 to September 2005 he served as Vice President of Research and Development of Thermage, Inc. (renamed Solta Medical). He is the inventor of 48 issued and numerous pending U.S. patents. Mr. Levinson is also a Board member at Pulse Biosciences, Connectwell, and Sensill. Mr. Levinson earned his B.S. in Mechanical Engineering from University of California at San Diego and holds an M.S in Computer Systems from the University of Phoenix.
Founder, Board Director
Ms. McCarthy is President and CEO of Cross Tack, Inc. a consulting firm providing clients a framework to address critical strategic decisions. She was previously Retired, President and CEO of SM&A, the world’s largest contract procurement service for defense, homeland security, health care, aerospace and information technology. Ms. McCarthy was also previously CFO of PIA Merchandising; Giant Group, Ltd.; and Wherehouse Entertainment. She began her career at Mellon Bank, where she became a Vice President in the Highly Leveraged Transaction Division.
Christoph Westphal, M.D., PhD
Dr. Westphal is co-founder and General Partner of Longwood Fund, Chair of TScan Therapeutics, Chair of Immunitas Therapeutics, and has spent 20 years as a life sciences CEO, entrepreneur, and investor. Dr. Westphal has been the co-founder, CEO, and lead investor of six biotechnology companies that have completed initial public offerings (IPOs) and created sustained market value of over $16 billion and have developed and received FDA approval for important drugs. These include: Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Acceleron Pharma, Inc. (NASDAQ: XLRN), Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT, acquired by GSK in 2008), Verastem (NASDAQ: VSTM), TScan Therapeutics, and Immunitas Therapeutics. Dr. Westphal is also co-founder of Longwood portfolio companies Alnara Pharmaceuticals (acquired by Eli Lilly), Axial Biotherapeutics, and Pyxis Oncology; and co-founder of Concert Pharmaceuticals (NASDAQ: CNCE). Dr. Westphal earned his M.D. from Harvard Medical School and Ph.D. in genetics from Harvard University; and he graduated with a B.A. summa cum laude and Phi Beta Kappa from Columbia University.